Electroconvulsive Therapy in Clozapine Refractory Schizophrenia
This trial is active, not recruiting.
|Treatments||electroconvulsive therapy (ect), clozapine|
|Phase||phase 1/phase 2|
|Sponsor||National Institute of Mental Health (NIMH)|
|Start date||December 2000|
|Trial size||64 participants|
|Trial identifier||NCT00042224, DSIR AT-SO, R01 MH60390|
This study will evaluate electroconvulsive therapy (ECT) in patients who have not responded adequately to clozapine.
|Endpoint classification||efficacy study|
|Intervention model||parallel assignment|
Male or female participants from 18 years up to 60 years old.
Inclusion criteria: - Receiving at least two 400 mg doses of chlorpromazine equivalents for at least 4 weeks (may include newer antipsychotics) - Having substantial psychotic symptoms despite at least 12 weeks of treatment (at least 8 weeks at a consistent dose)
|Official title||ECT in Clozapine Refractory Schizophrenia|
|Principal investigator||Georgios Petrides, MD|
|Description||ECT augmentation of clozapine will be compared to clozapine monotherapy in schizophrenic patients who continue to have psychotic symptoms despite optimal treatment with clozapine.|
Call for more information